(Q37693160)

22 August 2017

1 reference

title

Erythropoietic stimulating agents (English)

1 reference

22 August 2017

Ugo Testa

1

1 reference

22 August 2017

language of work or name

English

0 references

publication date

1 March 2010

1 reference

Expert Opinion on Emerging Drugs

22 August 2017

published in

1 reference

22 August 2017

volume

15

1 reference

22 August 2017

issue

1

1 reference

22 August 2017

page(s)

119-138

1 reference

Isolation and characterization of genomic and cDNA clones of human erythropoietin

22 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14728210903499273

Regulation of gene expression by oxygen: NF-kappaB and HIF-1, two extremes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903499273

HIFalpha targeted for VHL-mediated destruction by proline hydroxylation: implications for O2 sensing

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903499273

Targeting of HIF-alpha to the von Hippel-Lindau ubiquitylation complex by O2-regulated prolyl hydroxylation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903499273

C. elegans EGL-9 and mammalian homologs define a family of dioxygenases that regulate HIF by prolyl hydroxylation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903499273

Cobalt and desferrioxamine reveal crucial members of the oxygen sensing pathway in HepG2 cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903499273

Extracellular superoxide dismutase functions as a major repressor of hypoxia-induced erythropoietin gene expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903499273

Regulation of adult erythropoiesis by prolyl hydroxylase domain proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903499273

Erythroid-specific expression of the erythropoietin receptor rescued its null mutant mice from lethality

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903499273

Symmetric signaling by an asymmetric 1 erythropoietin: 2 erythropoietin receptor complex

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903499273

The erythropoietin receptor and its expression in tumor cells and other tissues

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903499273

Signal transduction in the erythropoietin receptor system

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903499273

A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903499273

The distal region and receptor tyrosines of the Epo receptor are non-essential for in vivo erythropoiesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903499273

Signals for stress erythropoiesis are integrated via an erythropoietin receptor-phosphotyrosine-343-Stat5 axis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903499273

Core erythropoietin receptor signals for late erythroblast development

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903499273

Stat5 activation enables erythropoiesis in the absence of EpoR and Jak2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903499273

Dosing patterns, hematologic outcomes, and costs of erythropoietic agents in predialysis chronic kidney disease patients with anemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903499273

The challenge of biosimilars

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903499273

Erythropoietins: a common mechanism of action

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903499273

Pure red-cell aplasia and antierythropoietin antibodies in patients treated with recombinant erythropoietin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903499273

Pure red-cell aplasia and epoetin therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903499273

Epoetin-associated pure red cell aplasia: past, present, and future considerations

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903499273

Structural analysis of the glycosylation of gene-activated erythropoietin (epoetin delta, Dynepo).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903499273

Pharmacokinetics and pharmacodynamics of epoetin delta in two studies in healthy volunteers and two studies in patients with chronic kidney disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903499273

Anemia management in patients on peritoneal dialysis: efficacy and safety of epoetin delta.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903499273

Enhancement of therapeutic protein in vivo activities through glycoengineering

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903499273

Darbepoetin alfa has a longer circulating half-life and greater in vivo potency than recombinant human erythropoietin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903499273

Investigation of the effects of altered receptor binding activity on the clearance of erythropoiesis-stimulating proteins: Nonerythropoietin receptor-mediated pathways may play a major role

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903499273

Cellular trafficking and degradation of erythropoietin and novel erythropoiesis stimulating protein (NESP).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903499273

Pharmacokinetics and pharmacodynamics of darbepoetin alfa and epoetin in patients undergoing dialysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903499273

Comparative erythropoietin receptor binding kinetics of C.E.R.A. and epoetin-beta determined by surface plasmon resonance and competition binding assay

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903499273

Intravenous methoxy polyethylene glycol-epoetin beta for haemoglobin control in patients with chronic kidney disease who are on dialysis: a randomised non-inferiority trial (MAXIMA).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903499273

Intravenous C.E.R.A. maintains stable haemoglobin levels in patients on dialysis previously treated with darbepoetin alfa: results from STRIATA, a randomized phase III study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903499273

What's fueling the biotech engine-2007.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903499273

Anemia of chronic disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903499273

The anemia of inflammation/malignancy: mechanisms and management

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903499273

The prevalence of anemia in patients with chronic kidney disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903499273

Clinical considerations and practical recommendations for the primary care practitioner in the management of anemia of chronic kidney disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903499273

TNF-alpha and IFN-gamma are overexpressed in the bone marrow of Fanconi anemia patients and TNF-alpha suppresses erythropoiesis in vitro.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903499273

Tumor necrosis factor-alpha inhibits generation of glycophorin A+ cells by CD34+ cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903499273

Linking anemia to inflammation and cancer: the crucial role of TNFalpha

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903499273

Iron metabolism in the anemia of chronic disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903499273

Dysregulated monocyte iron homeostasis and erythropoietin formation in patients with anemia of chronic disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903499273

A novel SHP-1/Grb2-dependent mechanism of negative regulation of cytokine-receptor signaling: contribution of SHP-1 C-terminal tyrosines in cytokine signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903499273

Normalization of hemoglobin level in patients with chronic kidney disease and anemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903499273

Mortality and target haemoglobin concentrations in anaemic patients with chronic kidney disease treated with erythropoietin: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903499273

Secondary analysis of the CHOIR trial epoetin-alpha dose and achieved hemoglobin outcomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903499273

Mechanism of increased mortality risk with erythropoietin treatment to higher hemoglobin targets

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903499273

Association of quarterly average achieved hematocrit with mortality in dialysis patients: a time-dependent comorbidity-adjusted model

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903499273

Effect of lowering blood pressure on cardiovascular events and mortality in patients on dialysis: a systematic review and meta-analysis of randomised controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903499273

Hemoglobin control, ESA resistance, and regular low-dose IV iron therapy: a review of the evidence

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903499273

Effect of variability in anemia management on hemoglobin outcomes in ESRD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903499273

Hemoglobin level variability: associations with mortality

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903499273

Hemoglobin variability and mortality in ESRD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903499273

Continuous intravenous sodium ferric gluconate improves efficacy in the maintenance phase of EPOrHu administration in hemodialysis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903499273

Ferric gluconate reduces epoetin requirements in hemodialysis patients with elevated ferritin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903499273

Recombinant human erythropoietins and cancer patients: updated meta-analysis of 57 studies including 9353 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903499273

Intravenous ferric gluconate significantly improves response to epoetin alfa versus oral iron or no iron in anemic patients with cancer receiving chemotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903499273

Clinical benefits and risks associated with epoetin and darbepoetin in patients with chemotherapy-induced anemia: a systematic review of the literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903499273

Effect of treatment with epoetin beta on short-term tumour progression and survival in anaemic patients with cancer: A meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903499273

Venous thromboembolism and mortality associated with recombinant erythropoietin and darbepoetin administration for the treatment of cancer-associated anemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903499273

Recombinant human erythropoiesis-stimulating agents and mortality in patients with cancer: a meta-analysis of randomised trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903499273

Effect of treatment with epoetin-beta on survival, tumour progression and thromboembolic events in patients with cancer: an updated meta-analysis of 12 randomised controlled studies including 2301 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903499273

September 2007 Update on EORTC Guidelines and Anemia Management with Erythropoiesis-Stimulating Agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903499273

Erythropoiesis-stimulating agents: favorable safety profile when used as indicated

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903499273

Erythropoietin receptors on tumor cells: what do they mean?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903499273

Erythroid-stimulating agents in cancer therapy: potential dangers and biologic mechanisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903499273

Supportive care and use of hematopoietic growth factors in myelodysplastic syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903499273

Erythropoietin and granulocyte-colony stimulating factor treatment associated with improved survival in myelodysplastic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903499273

Anemia and mortality in heart failure patients a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903499273

The potential role of erythropoietin in chronic heart failure: from the correction of anemia to improved perfusion and reduced apoptosis?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903499273

Transfusion strategy for primary knee and hip arthroplasty: impact of an algorithm to lower transfusion rates and hospital costs.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903499273

An individualized pre-operative blood saving protocol can increase pre-operative haemoglobin levels and reduce the need for transfusion in elective total hip or knee arthroplasty.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903499273

Functional mimicry of a protein hormone by a peptide agonist: the EPO receptor complex at 2.8 A

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903499273

Small peptides as potent mimetics of the protein hormone erythropoietin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903499273

Preclinical evaluation of Hematide, a novel erythropoiesis stimulating agent, for the treatment of anemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903499273

Chronic pharmacological and safety evaluation of Hematide, a PEGylated peptidic erythropoiesis-stimulating agent, in rodents.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903499273

Evaluation of the safety and pharmacodynamics of Hematide, a novel erythropoietic agent, in a phase 1, double-blind, placebo-controlled, dose-escalation study in healthy volunteers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903499273

CNTO 530: molecular pharmacology in human UT-7EPO cells and pharmacokinetics and pharmacodynamics in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903499273

HIF prolyl hydroxylase inhibition results in endogenous erythropoietin induction, erythrocytosis, and modest fetal hemoglobin expression in rhesus macaques

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903499273

Hydroxylation of hypoxia-inducible transcription factors and chemical compounds targeting the HIF-alpha hydroxylases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903499273

Inhibition of oxygen sensors as a therapeutic strategy for ischaemic and inflammatory disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903499273

Oral administration of K-11706 inhibits GATA binding activity, enhances hypoxia-inducible factor 1 binding activity, and restores indicators in an in vivo mouse model of anemia of chronic disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903499273

A potent erythropoietin-mimicking human antibody interacts through a novel binding site

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903499273

Hepcidin, the iron watcher

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903499273

The impact of selecting a high hemoglobin target level on health-related quality of life for patients with chronic kidney disease: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903499273

Efficacy and safety of epoetin alfa in critically ill patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903499273

10.1517/14728210903499273

21 January 2018

Identifiers

DOI

1 reference

22 August 2017

1 reference